KBI Biopharma Holds Ribbon Cutting for New Commercial Manufacturing Facility
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, held a ribbon-cutting at the company’s new state-of-the-art $150 million, 150,000 square-foot commercial manufacturing facility in Research Triangle Park (RTP), North Carolina. The location provides access to highly specialized talent and second-to-none technical and academic training.
Now fully operational, the site employs more than 200 people in production, supply chain, engineering, quality control, and quality assurance positions. That number is expected to grow to 350 by the end of the year, with the site’s intense focus on attracting and hiring high-performing employees. The ribbon-cutting, held on April 20th, was attended by the following:
- Tim Lowery, President, JSR Life Sciences
- Michael Landau, KBI, Interim Chief Operating Officer
- Jesse Kingg, KBI, Senior Vice President & Site Head, Patriot Park
- Laura Rowley, Ph.D., NC Biotech VP, Life Science Economic Development
- Geoff Durham, Durham Chamber President & CEO
KBI built this facility to support the manufacturing of mammalian-based products, starting with an undisclosed client’s late-phase clinical and commercial programs.
“Our new facility allows KBI to remain on the cutting-edge of the latest innovations in automation and digitalization,” said Kingg. “With the highest quality people, systems, and processes, we intend to be a true center of excellence and an exceptional place to work.”
In line with JSR Life Sciences’ ONEDigital initiative, the new facility will incorporate Manufacturing 4.0 principles through the design and integration of advanced technologies. Innovations include:
- Digital data collection systems, including electronic batch records, electronic logbooks, paperless materials management, and Laboratory Information Management Systems (LIMS) for quality control data management. These tools will enable real-time process and product quality monitoring and allow for future AI technology adoption.
- The facility has a ring corridor for suite access and a “science on display” viewing to showcase the facility to KBI clients.
KBI will use the facility as an option to provide clients with commercial launch material and market supply. KBI’s proven single-use platform ensures supply reliability with redundant equipment, automation, and full utility backup. Features include:
- Six 2,000-liter, single-use bioreactor systems and associated harvest and purification equipment can initially produce more than 70 batches per year and ramp up to meet additional demand.
- Advanced analytical services for commercial product characterization and release testing capabilities will support commercial launch and routine supply in tandem with the manufacturing operations.
“KBI prides itself on a creative approach to client collaboration,” said Landau. “Our customers turn to us to scale manufacturing processes suitable for commercial supply, and our scientific expertise with complex projects that deviate from standard planning protocol. It’s facilities like this and our strong client relationships that make this possible.”
This is the second major facility expansion announced by KBI within the last two years. KBI previously announced a new 5,600-square-meter biologic bulk drug substance manufacturing facility in Geneva, Switzerland. That facility is scheduled to be operational by mid-2022 and will employ more than 200 people in development, operations, and quality assurance positions.
About KBI Biopharma, Inc.
KBI Biopharma, a JSR Life Sciences company, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates into the clinic and beyond. KBI serves its global partners with multiple locations in Europe and the USA. www.kbibiopharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005061/en/
Contact information
KBI Biopharma, Inc. Company Inquiries
Aruna Mor
KBI Biopharma, Inc.
amor@kbibiopharma.com
KBI Biopharma, Inc. Media Contact
Kristin Schaeffer
CG Life
kschaeffer@cglife.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Network Failures Cost $5M A Year for More Than a Quarter of Global Businesses, According to Expereo1.7.2025 11:00:00 EEST | Press release
Network instability is taking a serious toll on global businesses, with over a quarter (28%) reporting revenue losses of up to $5 million due to network outages or poor performance. Alarmingly, an additional 23% have experienced losses exceeding $5 million. These findings come from an IDC InfoBrief commissioned by Expereo, titled “Enterprise Horizons 2025: Technology Leaders Priorities: Achieving Digital Agility.” Following a series of high-profile IT disruptions over the past year, ranging from cybersecurity breaches to connectivity failures, nearly half (49%) of global businesses have been compelled to re-evaluate their technology infrastructure, and 40% of global tech leaders say it’s caused networking and connectivity to rise higher up the C-suite agenda. Perhaps as a result, networking/connectivity now comes out on top in terms of the technologies global businesses will prioritise in terms of financial investment over the next 12 months (43%). This is followed by Cybersecurity (38
Record Financing for NeXtWind: €1.4 Billion for the Expansion of Wind Energy in Germany1.7.2025 10:52:00 EEST | Press release
NeXtWind, a leading renewable energy company, has secured €1.4 billion in debt financing. The agreement also includes an additional €1.3 billion in so-called accordion facilities, which can be activated in tranches over the coming years. This syndicated loan is the largest of its kind for an independent wind energy provider in Germany, and it opens the onshore wind market to debt investments from major financial institutions both domestically and internationally. NeXtWind will use the new financing to modernize more than half of its wind farms, increasing their generation capacity to over 1 GW by 2028. Subsequently, the company plans to further develop these wind farms into sustainable energy infrastructure hubs. “This financing is a significant milestone for NeXtWind and testament to the confidence in our business model,” explains Lars B. Meyer, Co-CEO of NeXtWind. “Thanks to this novel platform approach, we can optimize our wind farms more quickly and accelerate our growth. In the lo
Celero Ventures Opens $25 Million Early-Stage Fund to Investors Backing the Next Generation of European Software Companies1.7.2025 10:30:00 EEST | Press release
Celero Ventures, a new venture capital firm founded by experienced software operators Dave Wyatt and Nick Cochran, is now raising its debut $25 million fund to invest in early-stage startups across the UK and Europe. The fund, which is already 25% subscribed, targets pre-seed and seed-stage companies building next-generation AI and data infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250701820933/en/ Nick Cochran and David Wyatt (right) Founders of Celero Ventures Based in London, Celero Ventures is inviting limited partners (LPs) to join its mission of backing exceptional technical founders and accelerating their path to product-market fit and scalable growth. Wyatt and Cochran bring a rare combination of deep go-to-market (GTM) experience and startup leadership. Together, they helped scale both MuleSoft and Databricks—two of the most successful enterprise software companies of the past decade. Their experien
Cargill Sets a New Global Benchmark for More Sustainable Cocoa Supply Chains1.7.2025 10:00:00 EEST | Press release
Cargill today announced a transformation of its global cocoa supply chain, unveiling a series of interconnected investments that reduce carbon emissions, eliminate waste, and boost efficiency from cocoa origin countries in West Africa to processing hubs in Europe. The company’s upgrades span renewable energy, circular logistics, and smart infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250701468198/en/ Cargill today announced a transformation of its global cocoa supply chain, unveiling a series of interconnected investments that reduce carbon emissions, eliminate waste, and boost efficiency from cocoa origin countries in West Africa to processing hubs in Europe. “Sustainability isn’t a single project at Cargill—it’s how we operate,” said Emiel van Dijk, Managing Director of Cocoa & Chocolate Europe and West Africa. “From circular waste reuse to renewable transport and clean energy, we’re showing that climate a
Lyten Acquires Europe’s Largest Battery Energy Storage Systems Manufacturing Operation from Northvolt1.7.2025 10:00:00 EEST | Press release
Lyten, the supermaterial applications company and global leader in lithium-sulfur batteries, announced today the acquisition of Northvolt’s Dwa ESS operations in Gdansk, Poland, a 25,000 square meter (270,000 sq ft) battery energy storage systems (BESS) manufacturing and R&D facility. Northvolt Dwa ESS is the largest BESS manufacturing facility in Europe and was part of Northvolt Systems. The financial terms of the acquisition are not being released by either party. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250701098618/en/ Aerial view of the 25,000-square meter battery energy storage systems manufacturing facility, in Gdansk, Poland, acquired by Lyten from Northvolt. The facility, previously known as Northvolt Dwa ESS, is Europe’s largest energy storage systems manufacturing operation. The Northvolt acquisition accelerates expansion of Lyten’s lithium-sulfur batteries into Europe and provides Lyten with production capa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom